

Morten Ladekarl
Klinisk Professor, overlæge, Dr. Med.
Aalborg Universitetshospital
Klinisk Institut
Det Sundhedsvidenskabelige Fakultet
Klinik Kirurgi og Kræftbehandling
Kræftbehandling (Onkologi)
E-mail: morten.ladekarl@rn.dk, mla@dcm.aau.dk

Ansættelse

Aalborg Universitetshospital

Det Sundhedsvidenskabelige Fakultet

1 jan. 2019 → present

Klinisk professor

Klinisk professor

Klinisk Institut

Det Sundhedsvidenskabelige Fakultet

Gistrup, Danmark

1 jan. 2019 → 31 dec. 4712

Klinisk professor

Klinisk professor

Det Sundhedsvidenskabelige Fakultet

Gistrup, Danmark

1 jan. 2019 → 31 dec. 4712

Det Sundhedsvidenskabelige Fakultet

Gistrup, Danmark

1 jan. 2019 → present

Professor

Afdeling for Kræftbehandling

Det Sundhedsvidenskabelige Fakultet

1 jan. 2019 → present

Publikationer

Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis

Andersen, M. E., Hedegaard, E. M., Wen, S. W. C., Callesen, L. B., Szejniuk, W. M., Ladekarl, M., Timm, S., Spindler, K. G. & Frank, M. S., maj 2026, I: *Critical Reviews in Oncology/Hematology*. 221, 12 s., 105226.

Safety of [68Ga]Ga-FAPI-46 PET/CT including hemodynamic measurements and patient-reported outcomes in cancer patients

Bentestuen, M., Sylvest, C., Jensen, S. B., Soro, L. R., Knudsen, A., Ladekarl, M., Thorlacius-Ussing, O., Fendler, W. P. & Zacho, H. D., maj 2026, I: *Clinical Physiology and Functional Imaging*. 46, 3, 8 s., e70064.

Survival of Patients With Noncolorectal Non-Neuroendocrine Liver Metastases: A Nationwide Cohort Study From the Danish Liver Cancer Group

Mikkelsen, L. H., Larsen, P. N., Knøfler, L. A., Pless, T., Knudsen, A. R., Nielsen, S. D., Lousdal, M. L., Ladekarl, M., Stender, M. & Pommergaard, H. C., mar. 2026, I: *Journal of Surgical Research*. 319, s. 125-133 9 s.

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

Morken, S., Langer, S. W., Hjortland, G. O., Sundlöv, A., Hofslı, E., Ladekarl, M., Tabaksblat, E., Vestermark, L. W., Svensson, J., Knigge, U., Nunes, L., Glimelius, B., Pfeiffer, P., Aasebø, K., Assmus, J., Vassella, E., Lothe, I. M. B., Couvelard, A., Perren, A. & Knappskog, S. & 1 flere, Sorbye, H., 15 jun. 2026, I: *International Journal of Cancer*. 158, 12, s. 3217-3231 15 s.

Characteristics, Prognosis and Reasons for Opting-Out of Treatment in Patients with Untreated Pancreatic Cancer

Ladekarl, M. & Stender, M. T., feb. 2026, I: *Current Oncology*. 33, 2, 10 s., 116.

Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno-carcinoma after perioperative chemotherapy and radical resection

Larsen, A. C., Shim, S., Bæksgaard, L., Pfeiffer, P., Nordsmark, M., Brøndum, R., Sørensen, J. R., Motavaf, A. K. & Ladekarl, M., 11 jan. 2026, I: *Acta oncologica (Stockholm, Sweden)*. 65, s. 9-18 10 s.

Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis

Steiniche, M. M., Callesen, L. B., Vlk, E. H., Ventzel, L., Timm, S., Andersen, R. F., Lindgaard, S. C., Hansen, T. F., Ladekarl, M. & Spindler, K. L. G., dec. 2025, I: *Journal of Liquid Biopsy*. 10, 13 s., 100441.

Pembrolizumabbehandling af prostatacancer

Thostrup, A. H., Carus, A., Ladekarl, M. & Hjelholt, A. J., 24 nov. 2025, I: *Ugeskrift for læger [online]*. 187, 4 s., V05250410.

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST

Steiniche, M. M., Lindgaard, S. C., Chen, I. M., Johansen, J. S., Andersen, R. F., Hansen, T. F., Jensen, L. H., Rasmussen, L. S., Johansen, M. W., Ladekarl, M., Jakobsen, A. K. M. & Spindler, K. L. G., 15 nov. 2025, I: *Clinical Cancer Research*. 31, 22, s. 4720-4729 10 s.

Characteristics, treatment, and outcome of recurrent gastro-oesophageal adenocarcinoma after perioperative chemotherapy and radical resection - a national longterm real-world follow-up

Larsen, A. C., Shim, S., Bæksgaard, L., Pfeiffer, P., Nordsmark, M., Brøndum, R. F., Sørensen, J. R., Motavaf, A. K. & Ladekarl, M., 29 okt. 2025.

Is FAPI PET/CT After Neoadjuvant Chemotherapy Misleading? Early Findings from a Comparative Study with FDG PET/CT in Gastroesophageal Junction Cancer

Bentestuen, M., Borrisholt, M., Ladekarl, M., Thorlacius-Ussing, O. & Zacho, H. D., okt. 2025.

Is [⁶⁸Ga]Ga-FAPI-46 PET/CT Safe? A Safety Evaluation of the FAPI PET/CT Procedure with Haemodynamic Measurements and Patient-Reported Outcomes

Bentestuen, M., Sylvest, C., Ladekarl, M., Thorlacius-Ussing, O. & Zacho, H. D., sep. 2025, I: *EANM Innovation*. 1, Supplement, s. S692-S693 2 s., EP-0773.

Characteristics, treatment, and outcome of recurrent gastro-oesophageal adenocarcinoma after perioperative chemotherapy and radical resection - a national longterm real-world follow-up

Larsen, A. C., Shim, S., Bæksgaard, L., Pfeiffer, P., Nordsmark, M., Brøndum, R. F., Sørensen, J. R., Motavaf, A. K. & Ladekarl, M., 28 aug. 2025.

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Sorbye, H., Hjortland, G. O., Vestermark, L. W., Ladekarl, M., Svensson, J., Sundlöv, A., Janson, E. T., Garresori, H., Hofslı, E., Kersten, C., Elvebakken, H., Pfeiffer, P., Morken, S., Assmus, J., Lothe, I. M. B., Tabaksblat, E., Knigge, U., Couvelard, A., Perren, A. & Langer, S. W., 24 aug. 2025, I: *British Journal of Cancer*. 133, 3, s. 316-324 9 s.

Identification and validation of a ferroptosis-related long non-coding RNA signature as a prognostic biomarker for hepatocellular carcinoma

Yu, T., Chen, X., Li, S., Ladekarl, M. & Li, J., 30 jun. 2025, I: *Journal of gastrointestinal oncology*. 16, 3, s. 1092-1104 13 s.

ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel

Shim, S., Nielsen, M. B., Eld, M., Stenvang, J., Brøndum, R. F., Weber, B., Motavaf, A. K. & Ladekarl, M., jun. 2025, I: *Frontiers in Oncology*. 15, 12 s., 1558184.

Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma

Shim, S., Larsen, A. C., Bæksgaard, L., Pfeiffer, P., Nordmark, M., Sørensen, J. R., Motavaf, A. K. & Ladekarl, M., jun. 2025, I: *ESMO Gastrointestinal Oncology*. 8, 11 s., 100183.

Twenty-one-year report from the Danish Health Authority Expert Advisory Panel for review of treatment of 10 000 cancer patients

Ladekarl, M., Mørk, M. L., Albertsen, E. S., Nielsen, D., Lassen, U., Mau-Sørensen, M., Nielsen, C. M., Jakobsen, A. & Von Der Maase, H., 1 maj 2025, I: *Oncologist*. 30, 5, 8 s., oyaf059.

PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer

Shim, S., Reinacher-Schick, A., Kraeft, A. L., Pfeiffer, P., Tarpgaard, L. S., Ettrich, T. J., Kestler, A., Christensen, S., Jandu, H., Nawabi, M., Roest, N. L., Damstrup, L., Vestlev, P. M., Brünner, N., Stenvang, J. & Ladekarl, M., 24 apr. 2025, I: *Investigational New Drugs*. 43, 2, s. 337-347 11 s.

Longer survival with precision medicine in late-stage cancer patients

Mapendano, C. K., Nøhr, A. K., Sønderkær, M., Pagh, A., Carus, A., Lörincz, T., Haslund, C. A., Poulsen, L. Ø., Ernst, A., Bødker, J. S., Dahl, S. C., Sunde, L., Brüggemann, A. H., Vesteghem, C., Pedersen, I. S. & Ladekarl, M., jan. 2025, I: *ESMO Open*. 10, 1, 12 s., 104089.

Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients

Flak, R. V., Kofod-Olsen, E., Sølvsten, N. D., Naujokaite, G., Agger, R., Stender, M. T., Christensen, S., Shim, S., Poulsen, L. Ø., Detlefsen, S., Thorlasius-Ussing, O. & Ladekarl, M., 18 okt. 2024, I: *iScience*. 27, 10, 19 s., 111026.

Tumor-specific circulating cell-free DNA (ctDNA) and its clinical value in predicting response to palliative systemic treatment or survival in patients with pancreatic cancer: A systematic review and meta-analysis

Steiniche, M. M., Callesen, L. B., Vlk, E. H., Andersen, R. F., Hansen, T. F., Ladekarl, M. & Spindler, K.-L., sep. 2024, I: *Annals of Oncology*. 35, Suppl. 2, s. S923-S924 2 s., 1508P.

Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

Yu, J., Bai, Y., Cui, Z., Cheng, C., Ladekarl, M., Cheng, K.-C., Chan, K. S., Yarmohammadi, H., Mauriz, J. L. & Zhang, Y., 30 jun. 2024, I: *Journal of gastrointestinal oncology*. 15, 3, s. 1072-1081 10 s.

Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial

Benestuen, M., Ladekarl, M., Knudsen, A. & Zacho, H. D., 7 jun. 2024, I: *BMC Cancer*. 24, 1, 9 s., 699.

ProTarget – An investigator-initiated Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling. Trial, Overview and Status

Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B., Ladekarl, M., Lörincz, T., Belcaid, L., Gehl, J., Søndergaard, L., Eefsen, R., Hansen, K., Kodahl, A., Jensen, L., Holt, M., Oellegaard, T., Brøndum, L., Lorentzen, T., Yde, C. & Ahlborn, L. & 1 flere, Lassen, U., jun. 2024, *Abstract Book: Danske Kræftforskningsdage*. 1 udg. Danish Comprehensive Cancer Center, s. 16-17 2 s.

No survival effect of adjuvant chemotherapy in patients with node-negative pancreatic cancer – a target trial emulation study of real word data

Kirkegård, J., Ladekarl, M., Johannsen, I. R. & Mortensen, F., 24 maj 2024, I: *H P B*. 26, Suppl. 1, s. S121-S121 1 s.

The clinical outcomes of FOLFIRINOX in older patients with advanced pancreatic cancer in Denmark

Borhani-Khomani, G., S. Johansen, J., Madsen, K., Lindgaard, S. C., Z. Johansen, A., Parner, V. K., Rasmussen, L. S., Ladekarl, M., Yilmaz, M. K., Shim, S., Jensen, L. H., Pfeiffer, P., Bjerregaard, J. K., Andersen, F. & M. Chen, I., apr. 2024.

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial

Baeksgaard Jensen, L., Yilmaz, M., Nordmark, M., Möller, S., Elle, I. C., Ladekarl, M., Qvortrup, C. & Pfeiffer, P., apr. 2024, I: EClinicalMedicine. 70, 10 s., 102521.

Nordic NEC 2: Characteristics, treatment benefit and survival in a prospective cohort of 700 high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)

Sorbye, H., Hjortland, G. O., Vestermark, L., Ladekarl, M., Svensson, J., Jansson, E. T., Morken, S., Asmuss, J., Knigge, U., Couvelard, A., Perren, A. & Langer, S., mar. 2024.

Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation

Kirkegård, J., Ladekarl, M., Lund, A. & Mortensen, F., feb. 2024, I: Annals of Surgical Oncology. 31, 2, s. 1310-1318 9 s.

Germline variants in patients with end-stage cancer

Lundsgaard, M., Mapendano, C., Sønderkær, M., Ernst, A., Pedersen, I. S., Nohr, A. K., Ladekarl, M. & Sunde, L., 8 jan. 2024, I: European Journal of Human Genetics. 32, Suppl. 1, s. 557 1 s., P13.039.C.

Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation

Kirkegård, J., Ladekarl, M., Johannsen, I. R. & Mortensen, F., 3 jan. 2024, I: British Journal of Surgery. 111, 1, znad398.

Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms

Morken, S., Langer, S. W., Sundlöv, A., Vestermark, L. W., Ladekarl, M., Hjortland, G. O., Svensson, J. B., Tabaksblat, E. M., Haslerud, T. M., Assmus, J., Detlefsen, S., Couvelard, A., Perren, A. & Sorbye, H., 7 dec. 2023, I: British Journal of Cancer. 129, 12, s. 1930-1939 10 s.

Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms

Venizelos, A., Sorbye, H., Elvebakken, H., Perren, A., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlöv, A., Svensson, J., Garresori, H., Kersten, C., Hofslie, E., Detlefsen, S., Vestermark, L. W., Ladekarl, M., Tabaksblat, E. M. & Knappskog, S., 1 okt. 2023, I: Endocrine-Related Cancer. 30, 10, 12 s., e230057.

ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

Ladekarl, M., Shim, S., Ettrich, T. J., Kestler, A., Pfeiffer, P., Tarpgaard, L. S., Reinacher-Schick, A., Kraeft, A.-L., Stenvang, J., Zurlo, A. & Roest, N. L., okt. 2023, I: Annals of Oncology. 34, Suppl. 2, s. S907 1 s., 1641P.

Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Mouritzen, M. T., Ladekarl, M., Hager, H., Mattesen, T. B., Lippert, J. B., Frank, M. S., Nøhr, A. K., Egendal, I. B. & Carus, A., 8 sep. 2023, I: Cancers. 15, 18, s. 4480 4480.

Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab

Nowicka-Matus, K., Salkus, G., Sønderkær, M., Søskilde Pedersen, I., Ernst, A., Kubik, M., Takacs-Szabo, Z. & Ladekarl, M., 18 aug. 2023, I: JCO Precision Oncology. 7, e2300173.

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Rasmussen, L. S., Winther, S. B., M. Chen, I., Weber, B., Ventzel, L., Liposits, G., Johansen, J. S., Detlefsen, S., Egendal, I., Shim, S., Christensen, S., Pfeiffer, P. & Ladekarl, M., 16 jun. 2023, I: BMC Cancer. 23, 1, 552.

Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Ladekarl, M., apr. 2023, I: Chinese clinical oncology. 12, 2, s. 10 1 s., 10.

Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital

Ladekarl, M., Nøhr, A. K., Sønderkær, M., Dahl, S. C., Sunde, L., Vesteghem, C., Mapendano, C. K., Haslund, C. A., Pagh, A., Carus, A., Lörinicz, T., Nowicka-Matus, K., Poulsen, L. Ø., Laursen, R. J., Dybkær, K., Poulsen, B. K., Frøkjær, J. B., Brüggmann, A. H., Ernst, A. & Wanders, A. & 2 flere, Bøgsted, M. & Pedersen, I. S., mar. 2023, I: Acta Oncologica. 62, 3, s. 261-271 11 s.

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B. E., Ladekarl, M., Haslund, C. A., Harsløf, L., Belcaid, L., Gehl, J., Søndergaard, L., Eefsen, R. L., Hansen, K. H., Kodahl, A. R., Jensen, L. H., Holt, M. I., Oellegaard, T. H., Yde, C. W., Ahlborn, L. B. & Lassen, U., 22 feb. 2023, I: BMC Cancer. 23, 1, 12 s., 182.

Pd-L1 Blockade Followed by Irreversible Electroporation of a Liver Metastasis in Pancreatic Cancer Patients

Flak, R. V., Kofod-Olsen, E., Sølvsten, N. D., Naujokaite, G., Agger, R., Stender, M. T., Christensen, S., Shim, S., Poulsen, L. Ø., Detlefsen, S., Thorlasius-Ussing, O. & Ladekarl, M., 2023, SSRN: Social Science Research Network, 19 s.

Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?

Abou, C., Krastrup, T. W., Tenstad, H. B., Ren, J., Just, S. A., Ladekarl, M. & Stensballe, A., 22 dec. 2022, I: Expert Review of Precision Medicine and Drug Development. 7, 1, s. 162-168

Onkologisk behandling – af cancer pancreatis

Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 1 jul. 2022, Version 1.2 udg. Danske Multidisciplinære Cancer Grupper. 27 s.

O-4 Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophago-gastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas)

Pfeiffer, P., Yilmaz, M., Nordmark, M., Möller, S., Elle, I., Ladekarl, M., Winther, S., Qvortrup, C. & Baeksgaard, L., jun. 2022, I: Annals of Oncology. 33, Suppl. 4, s. S380

Implementing a data infrastructure for precision oncology projects leveraging REDCap

Vesteghem, C., Dahl, S. C., Brøndum, R. F., Sønderkær, M., Bødker, J. S., Schmitz, A., Weischenfeldt, J., Pedersen, I. S., Sommer, M., Rytter, A. S., Nielsen, M. M., Ladekarl, M., Severinsen, M. T., Dybkær, K., Grønbæk, K., El-Galaly, T., Roug, A. S. & Bøgsted, M., 12 maj 2022, medRxiv, 20 s. (medRxiv).

Dansk Pancreas Cancer Database (DPCD) – Resumé af Årsrapport 2020/2021

Styregruppen & Ladekarl, M. (Medlem af forfattergruppering), 24 jan. 2022, I: Ugeskrift for Læger. 2 s.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A.-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F. & Andersen, J. L. & 7 flere, Homann, P. H., Kristensen, E. B., Drivsholm, L. B., Bøgsted, M., Christensen, H. S., Pøhl, M. & Bjørnhart, B., 2022, I: Acta Oncologica. 61, 4, s. 409-416 8 s.

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Ladekarl, M., Rasmussen, L. S., Kirkegård, J., Chen, I., Pfeiffer, P., Weber, B., Skuladottir, H., Østerlind, K., Larsen, J. S., Mortensen, F. V., Engberg, H., Møller, H. & Frstrup, C. W., 2022, I: Acta Oncologica. 61, 3, s. 277-285 9 s.

Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI. Journal of Clinical Oncology

Schou, J. H. V., Roest, N., Ladekarl, M., Hansen, J. B. R., Hedtjaern, M. & Vestlev, P. M., 2022, I: Journal of Clinical Oncology. 40, Suppl. 4, 1 s., 185.

Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Tang, L. H., Wu, T., Marton, M. J., Peter, S., Kelsen, D. P. & Ku, G., dec. 2021, I: Cancer Medicine. 10, 23, s. 8365-8376 12 s.

Merkelcelle hudkræft

Naseri, S., Fagmedarbejdere, Naseri, S. (Medlem af forfattergruppering), Chakera, A. H. (Medlem af forfattergruppering), Steiniche, T. (Medlem af forfattergruppering), Ladekarl, M. (Medlem af forfattergruppering), Mogensen, M. (Medlem af forfattergruppering) & Kjeldsen, H. C. (Medlem af forfattergruppering), 17 nov. 2021, sundhed.dk.

Merkelcelle karcinom

Fagmedarbejdere, Naseri, S. (Medlem af forfattergruppering), Chakera, A. H. (Medlem af forfattergruppering), Steiniche, T. (Medlem af forfattergruppering), Ladekarl, M. (Medlem af forfattergruppering), Mogensen, M. (Medlem af forfattergruppering) & Kjeldsen, H. C. (Medlem af forfattergruppering), 17 nov. 2021, sundhed.dk.

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A.-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L. & Frary, J. M. C. & 5 flere, Drivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 28 sep. 2021, I: Cancers. 13, 19, 4846.

Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study

Achiam, M. P., Nordmark, M., Ladekarl, M., Olsen, A., Loft, A., Garbyal, R. S., Larsen, M. H., Ainsworth, A. P., Kristensen, T. S., Dikinis, S., Kjær, D. W., Bæksgaard, L., Siemsen, M., Nielsen, M. B., Schlander, S., Kramer, S., Katballe, N., Kruhlikava, I., Tabaksblat, E. & Fisker, R. V. & 6 flere, Mortensen, P. B., Holtved, E., Eckardt, J., Detlefsen, S., Naujokaite, G. & Lütken, C. D., sep. 2021, I: Acta Oncologica. 60, 9, s. 1091-1099 9 s.

Folfinrox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas

Butt, B. P., Stokmo, H. L., Ladekarl, M., Tabaksblat, E. M., Sorbye, H., Revheim, M. E. & Hjortland, G. O., sep. 2021, I: Annals of Oncology. 32, 5, s. S915-S915 1108P.

Merkelcellekarcinom

Naseri, S., Steiniche, T., Ladekarl, M., Hölmich, L. R., Langer, S. W., Tabaksblat, E. M., Junker, N. & Chakera, A. H., 26 jul. 2021, I: Ugeskrift for Laeger. 183, 3 s., V03210260.

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Dyhl-Polk, A., Mikkelsen, M. K., Ladekarl, M. & Nielsen, D. L., 16 jun. 2021, I: Journal of Clinical Medicine . 10, 12, 2662.

Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study

Rasmussen, L. S., Frstrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Bøgsted, M. & Falkmer, U. G., 22 maj 2021, I: Pancreas. 50, 5, s. 685-695 11 s.

Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms

Pommegaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlöf, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., maj 2021, I: Journal of Neuroendocrinology. 33, 5, e12967.

A phase II-study of electroporation potentiated immunotherapy in liver metastatic pancreatic cancer (EPIC-1)

Flak, R. V., Poulsen, L. Ø., Stender, M. T., Naujokaite, G., Tcacenco, O., Wanders, A., Detlefsen, S., Agger, R., Kofod-Olsen, E., Thorlacius-Ussing, O. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 51 40

Beskrivelse af den nationale MDT konference for pancreascancer: deltagelse og tilbud om operation

Engberg, H., Møller, H., Hansen, C. P., Burgdorf, S., Fallentin, E., Fristrup, C. W., Jensen, B. V., Jensen, J. W., Knudsen, A. R., Ladekarl, M., Larsen, L. P. S., Mortensen, F. V., Kissmeyer-Nielsen, P., Sall, M., Stender, M. T., Storkholm, J. H., Gyllenborg, J. & Hillingsø, J., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 164 145

Hans Jørgen Gottlieb Gundersen: 2.5.1943-1.2.2021

Nyengaard, J. R., Ladekarl, M., Dorph-Petersen, K.-A., Bendtsen, T. F., Nielsen, K. & Sørensen, F. B., 2021, I: Ugeskrift for Læger.

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A.-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L. & Frary, J. M. C. & 5 flere, Drivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 2021.

Scrotal Paget's disease associated with metastatic carcinoma with apocrine features and ERBB2-amplification/HER2 overexpression responding well to weekly paclitaxel combined with trastuzumab and pertuzumab. A case report

Nowicka-Matus, K., Salkus, G., Pedersen, I. S., Sønderkær, M., Ernst, A., Takacs-Szabó, Z. & Ladekarl, M., 2021, *Danske Kræftforskningsdage: Abstract Book*. s. 152 133

Udredning og behandling af Cholangiocarcinom

Larsen, P. N. (Redaktør), Rasmussen, A., Schultz, N., Mortensen, F. V., Knudsen, A. R., Stender, M. T., Sall, M., Pless, T., Vistisen, K., Larsen, F. O., Weber, B., Mortensen, H. R., Boysen, A. K., Ladekarl, M., Risum, S., Jensen, L. H., Fallentin, E., Willemoie, G., Hamilton, S. & Kjær, M. & 4 flere, Grønbæk, H., Villadsen, G., Loft, A. & Schultz, L., 27 okt. 2020, Version 1.0 udg. Danske Multidisciplinære Cancer Grupper. 72 s.

Onkologisk behandling - af cancer pancreatis

Ladekarl, M., Weber, B., Jensen, B. V. & Pfeiffer, P., 16 okt. 2020, Version 1.0 udg. Danske Multidisciplinære Cancer Grupper. 24 s.

PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy

Steiniche, T., Marsico, M. A., Siegel, A. B., Gronbaek, H., Ha, S., Hong, J. Y., Paik, Y.-H., Georgsen, J., Pommergaard, H.-C., Ladekarl, M., Webber, A., Liu, X., Kachurak, A., Skaarup, K., Lee, J. & Lim, H. Y., 1 sep. 2020, I: *Annals of Oncology*. 31, Suppl. 4, s. S697 1006P.

Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort

Mouritzen, M., Bjoernhart, B., Poehl, M., Ladekarl, M., Vesteghem, C., Boegsted, M., Nielsen, A. W. M., Meldgaard, P., Hansen, K. H., Larsen, J. W. W., Kristiansen, C., Wedervang, K., Bareid-Oestby, A.-C., Frank, M. S., Persson, G., Kristensen, E. B., Homann, P. H. & Carus, A., 1 sep. 2020, I: *Annals of Oncology*. 31, Suppl. 4, s. S858 1 s., 1334P .

Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump

Ladekarl, M., Schou, J. H. V., Roest, N. L., Stenvang, J., Brüner, N. & Vestlev, P. M., 1 sep. 2020, I: *Annals of Oncology*. 31, Suppl. 4, s. S503-S504 2 s., 605TiP .

Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers

Steiniche, T., Ladekarl, M., Georgsen, J. B., Andreasen, S., Busch-Sorensen, M., Zhou, W., Marton, M. J., Pruitt, S. K., Jin, F. & Liaw, K.-L., 19 aug. 2020, I: *Future Science OA*. 6, 8, 11 s., FSO616.

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Díaz-González, Á., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L. L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C., Sacco, R., Matilla, A. M., Hernández-Guerra, M., Aballay Soteras, G., Wörns, M.-A., Pinter, M., Varela, M., Ladekarl, M., Chagas, A. L., Mínguez, B., Arenas, J. I., Granito, A. & Sánchez-Torrijos, Y. & 29 flere, Rojas, Á., Rodríguez de Lope, C., Alvares-da-Silva, M. R., Pascual, S., Rimassa, L., Lledó, J. L., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara, M., Perelló, C., Lue, A., Sala, M., Gallego, A., Coll, S., Hernáez, T., Piñero, F., Pereira, G., França, A., Marín, J., Anders, M., Mello, V., Lozano, M., Nault, J. C., Menéndez, J., García Juárez, I., Bruix, J. & Reig, M., jun. 2020, I: *Liver International*. 40, 6, s. 1467-1476 10 s.

Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma

Naseri, S., Steiniche, T., Georgsen, J. B., Thomsen, R., Ladekarl, M., Heje, M., Damsgaard, T. E. & Bønnelykke-Behrndtz, M. L., 6 apr. 2020, I: *Cancers*. 12, 4, s. 1-11 11 s., 888.

Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

Rasmussen, L. S., Frstrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Detlefsen, S., Bøgsted, M. & Falkmer, U. G., apr. 2020, I: *European Journal of Cancer*. 129, s. 50-59 10 s.

Pilot study experiences with hyperpolarized [1-13 C]pyruvate MRI in pancreatic cancer patients

Stødkilde-Jørgensen, H., Laustsen, C., Hansen, E. S. S., Schulte, R., Ardenkjaer-Larsen, J. H., Comment, A., Frøkiaer, J., Ringgaard, S., Bertelsen, L. B., Ladekarl, M. & Weber, B., mar. 2020, I: *Journal of Magnetic Resonance Imaging*. 51, 3, s. 961-963 3 s.

Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis

Kirkegård, J., Gaber, C., Lund, J. L., Hinton, S. P., Ladekarl, M., Heide-Jørgensen, U., Cronin-Fenton, D. & Mortensen, F. V., feb. 2020, I: *Cancer epidemiology*. 64, 9 s., 101647.

Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective

Naseri, S., Steiniche, T., Ladekarl, M., Bønnelykke-Behrndtz, M. L., Hölmich, L. R., Langer, S. W., Venzo, A., Tabaksblat, E., Klausen, S., Skaarup Larsen, M., Junker, N. & Chakera, A. H., feb. 2020, I: *Cancers*. 12, 3, 13 s., 554.

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønabæk, H., Ladekarl, M., Welin, S., Weber Vestermark, L., Arola, J., Osterlund, P., Knigge, U., Sørbye, H., Micke, P., Grimelius, L., Grönberg, M. & Tiensuu Janson, E., 2020, I: *PLOS ONE*. 15, 12, e0243900.

Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients

Pommegaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E., Vestermark, L., Tiensuu Janson, E., Hansen, C. P., Ladekarl, M., Garresori, H., Langer, S. & Knigge, U., 2020, *17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, 11-13 March 2020, Barcelona, Spain, Virtual Conference*. s. 319

Impact of Concurrent Acute Pancreatitis on Pancreatic Cancer Stage, Treatment, and Prognosis: A Study of Two Cohorts

Kirkegård, J., Gaber, C., Lund, J. L., Peacock-Hinton, S., Ladekarl, M., Heide-Jørgensen, U., Cronin Fenton, D. & Mortensen, F. V., 3 jun. 2019.

The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study

Skau Rasmussen, L., Vittrup, B., Ladekarl, M., Pfeiffer, P., Karen Yilmaz, M., Østergaard Poulsen, L., Østerlind, K., Palnæs Hansen, C., Bau Mortensen, M., Viborg Mortensen, F., Sall, M., Detlefsen, S., Bøgsted, M. & Wilki Frstrup, C., jun. 2019, I: *Acta Oncologica*. 58, 6, s. 864-871 8 s.

A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis

Diaz-Gonzalez, A., Sanduzzi-Zamparelli, M., Gomes da Fonseca, L., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C. R. G., Sacco, R., Matilla, A. M., Guerra, M. H., Aballay Soteras, G. A., Marcus, W., Pinter, M., Varela, M., Ladekarl, M., Lopes Chagas, A., Minguez, B., Ignacio Arenas Ruiz-Tapiador, J., Granito, A. & Sánchez, Y. & 29 flere, Rojas, A., Rodriguez De Lope, C., Reis Álvares-Da-Silva, M., Pascual, S., Rimassa, L., Luis Lledó, J., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara Gómez, M., Perello, C., Lué, A., Sala, M., Gallego Moya, A., Coll, S., Hernaez Alsina, T., Pinero, F., Pereira, G., Vianey Callado França, A., Callado França, V., Margarita Anders, M., Mello, V., Del Mar Lozano, M., Charles Nault, J., María Menéndez, J., García Juárez, I., Bruix, J. & Reig, M., apr. 2019, I: *Journal of Hepatology*. 70, 1S, s. E599-E600 FRI-462.

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature

Overby, A., Duval, L., Ladekarl, M., Laursen, B. E. & Donskov, F., feb. 2019, I: *Clinical genitourinary cancer*. 17, 1, s. e32-e37 6 s.

T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Wu, T., Savage, M. J., Marton, M. J., Kang, S. P., Peter, S. A., Kelsen, D. P. & Ku, G. Y., 2019, I: *Journal of Clinical Oncology*. 37, Supl. 4, s. 26 1 s.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Ali, A. S., Grönberg, M., Langer, S. W., Ladekarl, M., Hjortland, G. O., Vestermark, L. W., Österlund, P., Welin, S., Grønbæk, H., Knigge, U., Sorbye, H. & Janson, E. T., 6 mar. 2018, I: *Medical Oncology*. 35, 4, s. 47

Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study

Madsen, A. H., Ladekarl, M., Villadsen, G. E., Grønbæk, H., Sørensen, M. M., Stribolt, K., Verwaal, V. J. & Iversen, L. H., feb. 2018, I: *Annals of Surgical Oncology*. 25, 2, s. 422-430 9 s.

Association of PD-L1 expression with prognosis among patients with 10 select cancers

Steiniche, T., Ladekarl, M., Bæhr Georgsen, J., Andreassen, S., Busch-Sørensen, M., Zhou, W., Pruitt, S. K., Joe, A. K. & Liaw, K.-L., 2018, I: *Annals of Oncology*. 29, Suppl. 8, s. viii15 53PD.

Geographical Residency Influences Pancreatic Cancer Survival: A Danish Nationwide Population-based Cohort Study

Kirkegård, J., Ladekarl, M., Fristrup, C., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018.

Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study

Kirkegård, J., Ladekarl, M., Fristrup, C. W., Hansen, C. P., Sall, M. & Mortensen, F. V., 2018, I: *PLOS ONE*. 13, 8, 11 s., e0202486.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Galleberg, R. B., Knigge, U., Tiensuu Janson, E., Vestermark, L. W., Haugvik, S.-P., Ladekarl, M., Langer, S. W., Grønbæk, H., Österlund, P., Hjortland, G. O., Assmus, J., Tang, L., Perren, A. & Sorbye, H., sep. 2017, I: *European Journal of Surgical Oncology*. 43, 9, s. 1682-1689 8 s.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Ali, A. S., Grönberg, M., Federspiel, B., Scoazec, J.-Y., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Arola, J., Österlund, P., Knigge, U., Sorbye, H., Grimelius, L. & Janson, E. T., 2017, I: *P L o S One*. 12, 11, 15 s., e0187667.

Danish Pancreatic Cancer Database

Fristrup, C., Dettlefsen, S., Hansen, C. P. & Ladekarl, M., 25 okt. 2016, I: *Clinical Epidemiology*. 8, s. 645-648 4 s.

Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art
Tabaksblat, E. M., Langer, S. W., Knigge, U., Grønbæk, H., Mortensen, J., Petersen, R. H., Federspiel, B. H. & Ladekarl, M., jan. 2016, I: Acta Oncologica. 55, 1, s. 3-14 12 s.

BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping
Sharma, M. B., Carus, A., Sunde, L., Hamilton-Dutoit, S. & Ladekarl, M., 2016, I: Acta Oncologica. 55, 3, s. 377-381 5 s.

A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors

Larsen, A. C., Holländer, C., Duval, L., Schønnemann, K., Achiam, M., Pfeiffer, P., Yilmaz, M. K., Thorlacius-Ussing, O., Bæksgaard, L. & Ladekarl, M., 2015, I: Annals of Surgical Oncology. 22, 5, s. 1540-1547

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients

Olsen, I. H., Holt, N., Langer, S. W., Hasselby, J. P., Grønbæk, H., Hillingsø, J., Mahmoud, M., Ladekarl, M., Iversen, L. H., Kjær, A., Federspiel, B. H. & Knigge, U., 2015, I: PLOS ONE. 10, 2, s. e0117627

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jääntti, C., Sundin, A., Sundlöv, A., Thiis-Evensen, E. & Knigge, U., okt. 2014, I: Acta oncologica (Stockholm, Sweden). 53, 10, s. 1284-97 14 s.

Postoperative but not preoperative treatment with Sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A.-S., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 15 apr. 2014.

Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer

Kræmer, P. C., Schmidt, H. H. & Ladekarl, M., apr. 2014, I: Danish Medical Journal. 61, 4, A4819.

Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments

Carus, A., Donskov, F., Switten Nielsen, P., Hager, H., Nedergaard, B., Steiniche, T. & Ladekarl, M., 2014, I: The Journal of OncoPathology. 2, 2, s. 1-9 9 s.

Tumour-associated CD66b + neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer

Carus, A., Ladekarl, M., Hager, H., Nedergaard, B. & Donskov, F., 1 maj 2013, I: British Journal of Cancer. 108, 10, s. 2116-2122 7 s.

Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: A case description

Ladekarl, M., Villadsen, G. E., Rudbeck, A. R., Aagenæs, Ø., Nielsen, J. E., Hamilton-Dutoit, S. & Nordmark, M., 1 jan. 2013, I: Case Reports in Oncology. 6, 1, s. 98-103 6 s.

Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali.

Hangaard, J., Andersen, M., Laursen, T., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K., Poulsen, P. L., Friberg, A., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Knigge, U. P. & Grønbæk, H., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger og GH-receptorantagonist til akromegali.*

Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer

Knigge, U. P., Grønbæk, H., Ladekarl, M., Schaffalitzky de Muckadell, O. B., Wilson, B., Hangaard, J., Andersen, M., Laursen, T., Friberg, A., Nielsen, E. H., Storm, T. L., Rasmussen, Å. K. & Poulsen, P. L., 2013, *Baggrundsnotat for brug af langtidsvirkende somatostatinanaloger til neuroendokrine tumorer.* 13 s.

Diffuse abdominal splenosis mimicking peritoneal metastases in a 35-year-old man with a resectable carcinoma of the ampulla of Vater

Sorensen, S. F., Mortensen, F. V., Hellberg, Y. & Ladekarl, M., 2013, I: Case Reports in Oncology. 6, 3, s. 467-71 5 s.

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia
Carus, A., Gurney, H., GebSKI, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., Maase, H. V. D. & Donskov, F., 2013, I: Journal of Translational Medicine. 11, 8, 10 s., 189.

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability
Køstner, A. H., Sørensen, M., Olesen, R. K., Grønbæk, H., Lassen, U. & Ladekarl, M., 2013, I: Scientific World Journal. 2013, s. 931972

Sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A.-S., Sasanuma, H., Nyengaard, J. R., Hamilton-Dutoit, S. J., Ladekarl, M. & Mortensen, F. V., 2013.

Tumor-associated CD66b+neutrophil and CD8+lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments

Carus, A., Ladekarl, M., Nielsen, P. S., Hager, H., Nedergaard, B. S., Steiniche, T. & Donskov, F., 2013, I: Journal of Clinical Oncology. 31, 15, suppl.

Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome
Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2013, I: Lung Cancer. 81, 1, s. 130-137 8 s.

Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage

Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Switten Nielsen, P. & Donskov, F., 2012, I: Journal of Clinical Oncology. 30, Suppl. 15, 1 s., e21110.

Dansk Pancreas Cancer Database

Frstrup, C., Palnæs Hansen, C., Ladekarl, M. & Mortensen, M. B., 2012, I: Ugeskrift for Læger. 174, 42, s. 2545 1 s.

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Pappot, H., Christensen, I. J., Høyer-Hansen, G., Sørensen, M., Skov, B. G., Buyschaert, I., Carmeliet, P. & Lassen, U., 2012, I: Acta Oncologica. 51, 2, s. 234-42 9 s.

Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs

Zukauskaitė, R., Hjorthgaur, K., Poulsen, P. L., Baerentzen, S. & Ladekarl, M., 30 jun. 2011, I: Acta Oncologica. 50, 8, s. 1255-9 5 s.

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Sørensen, M., Christensen, I. J. & Skov, B. G., 2011, I: Cancer Biology & Therapy. 11, 8, s. 732-9 8 s.

Ovariemetastaser fra ventrikelcancer diagnosticeret med diffusionsvægtet 3T-magnetisk resonans-skanning

Røhl, L., Nellemann, H. M., Ladekarl, M. & Pedersen, E. M., 2011, I: Ugeskrift for Læger. 173, 16-17, s. 1212-3 2 s.

Toxicity-adjusted dose (TAD) administration of chemotherapy: Effect of baseline and nadir neutrophil count in patients with breast, ovarian, and lung cancer?

Carus, A., Donskov, F., GebSKI, V., Kefford, R., Wilcken, N., Hui, R., Harnett, P., Ladekarl, M., Maase, H. V. D. & Gurney, H., 2011, I: Journal of Clinical Oncology. 29, Suppl. 15, 1 s., e21023.

Onkologisk behandling af patienter med pancreascancer

Ladekarl, M., Jensen, B. V. & Pfeiffer, P., 3 maj 2010, I: Ugeskrift for Læger. 172, 18, s. 1373-6 4 s.

A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years
Nedergaard, B., Ladekarl, M., Nyengaard, J. R. & Nielsen, K., 2008, I: *Gynecologic Oncology*. 108, 1, s. 106-111 6 s.

Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer
Nedergaard, B., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2008. 1 s.

Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer
Nedergaard, B. S., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2007, I: *British Journal of Cancer*. 97, 8, s. 1135-1138 4 s.

Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri
Nedergaard, B., Nielsen, K., Nyengaard, J. R. & Ladekarl, M., 2007, I: *Acta Pathologica Microbiologica et Immunologica Scandinavica*. 115, 12, s. 1321-30 9 s.

Choice of Methodology for Quantifying Cancer Structures in Tissue Sections: A Comparison of 2- and 3-Dimensional Estimators of Mitotic Activity, Cellularity and Nuclear Size in Breast Cancer
Ladekarl, M., apr. 2004, I: *Analytical and quantitative cytology and histology*. 26, 2, s. 97-104 8 s.

Detection of circulating tumour lysate-reactive CD4+ T cells in melanoma patients
Ladekarl, M., Agger, R., Fleischer, C. C., Hokland, M., Hulgaard, E. F., Kirkin, A., von der Maase, H., Petersen, M. S., Rytter, C., Zeuthen, J. & Gundersen, H. J. G., 2004, I: *Cancer Immunology, Immunotherapy*. 53, s. 560-566 7 s.

Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas
Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S.-C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J. & Raleigh, J. A., apr. 2003, I: *Radiotherapy & Oncology*. 67, 1, s. 35-44 10 s.

Nye behandlingsperspektiver ved duktalt carcinoma in situ mammae: New therapeutic perspectives in breast ductal carcinoma in situ
Ladekarl, M., Grau, C. & Andersen, J., 2001, I: *Ugeskrift for Laeger*. 163, 37, s. 5014-5017 4 s., 4979.

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
Horsman, M. R., Ehrnrooth, E., Ladekarl, M. & Overgaard, J., 1 nov. 1998, I: *International Journal of Radiation Oncology, Biology, Physics*. 42, 4, s. 895-898 4 s.

Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas
Jensen, V., Sørensen, F. B., Bentzen, S. M., Ladekarl, M., Nielsen, O. S., Keller, J. & Jensen, O. M., jun. 1998, I: *Histopathology*. 32, 6, s. 536-46 11 s.

Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors
Ladekarl, M., 1998, I: *APMIS, Supplement*. 106, Suppl. 79, s. 5-34 30 s.

Total number of cancer cell nuclei and mitoses in breast tumors estimated by the optical disector
Ladekarl, M., Jensen, V. & Nielsen, B., aug. 1997, I: *Analytical and quantitative cytology and histology*. 19, 4, s. 329-337 9 s.

The prognostic value of MIB-2 and bcl-2 expression in soft tissue sarcomas.
Jensen, V., Sørensen, F. B., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., mar. 1996.

The prognostic value of quantitative histopathology in soft tissue fibrosarcomas.

Ladekarl, M., Jensen, V., Sørensen, F. B., Nielsen, O. S. & Jensen, O. M., mar. 1996.

The prognostic value of quantitative histopathology in soft tissue malignant fibrous histiocytomas.

Sørensen, F. B., Jensen, V., Ladekarl, M., Nielsen, O. S. & Jensen, O. M., mar. 1996.

Objektiv histologisk gradering af planocellulær og adenoskvamøs lungecancer

Ladekarl, M., Hansen, T. B., Nielsen, R. H., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1996, I: Ugeskrift for læger. 158, 40, s. 5611-5615 5 s.

Stereologic estimation of breast tumor size

Ladekarl, M., Jensen, V. & Nielsen, B., 1996, I: Analytical and quantitative cytology and histology. 18, 2, s. 151-157 7 s.

Quantitative histopathology in lymph node-negative breast cancer. Prognostic significance of mitotic counts

Ladekarl, M. & Jensen, V., nov. 1995, I: Virchows Archiv. 427, 3, s. 265-270 6 s.

Objective malignancy grading of squamous cell carcinoma of the lung. Stereologic estimates of mean nuclear size are of prognostic value, independent of clinical stage of disease

Ladekarl, M., Bæk-Hansen, T., Henrik-Nielsen, R., Mouritzen, C., Henriques, U. & Sørensen, F. B., 1 sep. 1995, I: Cancer. 76, 5, s. 797-802 6 s.

The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer

Jensen, V., Ladekarl, M., Holm-Nielsen, P., Melsen, F. & Sørensen, F. B., aug. 1995, I: Journal of Pathology. 176, 4, s. 343-352 10 s.

Quantitative histopathology in ductal carcinoma of the breast. Prognostic value of mean nuclear size and mitotic counts

Ladekarl, M., 15 apr. 1995, I: Cancer. 75, 8, s. 2114-2122 9 s.

Significance of variations in section mounting technique for nuclear stereology and morphology in urinary bladder neoplasms

Ladekarl, M. & Svanholm, H., mar. 1995, I: APMIS. 103, 7-8, s. 892-896 5 s.

Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer

Jensen, V. & Ladekarl, M., 1995, I: Journal of Clinical Pathology. 48, 5, s. 429-432 4 s.

The influence of tissue processing on quantitative histopathology in breast cancer

Ladekarl, M., maj 1994, I: Journal of Microscopy. 174, 2, s. 93-100 8 s.

Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer: An investigation of various sampling schemes

Baak, J. P. A., Ladekarl, M. & Sørensen, F. B., jan. 1994, I: Human Pathology. 25, 1, s. 80-85 6 s.

Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast

Ladekarl, M. & Sørensen, F. B., dec. 1993, I: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 12, s. 895-903 9 s.

Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast

Ladekarl, M. & Sørensen, F. B., 1 nov. 1993, I: Cancer. 72, 9, s. 2602-2611 10 s.

Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas
Sørensen, F. B., Gamel, J. W., Jensen, O. A., Ladekarl, M. & McCurdy, J., maj 1993, I: APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 101, 5, s. 358-68 11 s.

Presse/medie

10 afklarende svar fra kræftlægen

Ladekarl, M.
28/05/2020
1 Mediebidrag

Behandling af kræft i bugspytkirtlen

Ladekarl, M.
07/10/2022
1 element af Mediedækning

CheckMate 9DW bekræfter potentialet ved dobbelt-immunterapi i første linje til avanceret leverkræft

Ladekarl, M.
04/06/2024
1 element af Mediedækning

Danske kræftafdelinger behandler bugspytkirtelkræft forskelligt, og det påvirker levetiden

Ladekarl, M.
16/03/2022 → 23/03/2022
4 elementer af Mediedækning

Debat: Løhdes vagt giver nej-rekord for danske patienter

Weinreich, U. M. & Ladekarl, M.
12/01/2026
1 element af Mediedækning

Debat: Løhdes vagt giver nej-rekord for danske patienter

Weinreich, U. M. & Ladekarl, M.
22/01/2026
1 element af Mediedækning

Debat: Præcisionsmedicin fortjener en chance – præcis som patienterne

Ladekarl, M.
21/08/2025
1 element af Mediedækning

Ekspérimentel behandling: 54 dødeligt syge danskere fik i 2023 en sidste mulighed for behandling

EI-Galaly, T. C. & Ladekarl, M.
04/12/2024
1 element af Mediedækning

Endnu en KRAS-hæmmer: Lovende effekt mod ikke-småcellet lungekræft

Ladekarl, M.
13/04/2021
1 element af Mediedækning

Flere kræftpatienter vil have gavn af upfront gensekventering

Ladekarl, M.
20/09/2020 → 21/09/2020
2 elementer af Mediedækning

Formand for kræftlæger: Vi venter stadig på biomarkørernes store gennembrud

Ladekarl, M.

04/12/2019

1 element af Mediedækning

Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft

Ladekarl, M.

06/07/2020

1 element af Mediedækning

Forskere vil afprøve immunterapi og elektriske impulser mod bugspytkirtelkræft

Ladekarl, M.

01/09/2020

2 elementer af Mediedækning

Første gang nogensinde: KRAS-hæmmer med tydelig effekt

Ladekarl, M.

21/10/2020

1 element af Mediedækning

Første overlevelsesresultater for KRAS-hæmmer mod lungekræft er flotte, men

Ladekarl, M.

14/06/2021

1 element af Mediedækning

KRAS-hæmmer viser lovende effekt mod tarmkræft

Ladekarl, M.

21/09/2021

1 element af Mediedækning

Kræftdødeligheden falder markant i Danmark

Ladekarl, M.

13/06/2023 → 14/06/2023

2 elementer af Mediedækning

Kræftens Bekæmpelse uddeler støtte til kræftforskning

Ladekarl, M.

19/08/2020 → 21/08/2020

4 elementer af Mediedækning

Kræftlægen har ordet

Ladekarl, M.

28/05/2020

1 element af Mediedækning

Læger håber på en ny kategori i kræftbehandlingen

Ladekarl, M.

22/01/2021

1 element af Mediedækning

Morten Ladekarl er ny professor i onkologi

Ladekarl, M.

17/01/2019

2 elementer af Mediedækning

Ny blodprøvetest skal forbedre behandling af kræft i bugspytkirtlen

Ladekarl, M.

17/05/2026

1 element af Mediedækning

Nye overlevedesdata styrker optimisme om KRAS-hæmmer mod lungekræft

Ladekarl, M.

18/05/2022

1 element af Mediedækning

Ny metode til screening for kræft i bugspytkirtlen?

Ladekarl, M.

25/01/2024

1 element af Mediedækning

Ny metode til screening for kræft i bugspytkirtlen?

Ladekarl, M.

05/02/2024

1 element af Mediedækning

Nyt om navne

Ladekarl, M.

28/01/2019

1 element af Mediedækning

Nyt studie: KRAS-hæmmer viser igen lovende effekt mod KRAS-muteret NSCLC

Ladekarl, M.

02/02/2021

1 element af Mediedækning

Ny vaccine giver håb i mørket for patienter, der kan opereres for bugspytkirtelkræft

Ladekarl, M.

23/08/2024

1 element af Mediedækning

Ny vaccine kan være et lys i mørket for patienter med resektabel bugspytkirtelkræft

Ladekarl, M.

14/07/2024

1 element af Mediedækning

Personlig medicin har stort potentiale - men validering af effekt kræver enorme datamængder

Ladekarl, M.

12/03/2025 → 14/03/2025

5 elementer af Mediedækning

Personlig medicin virker - men ofte kan danske kræftpatienter ikke få adgang til behandlingerne

Ladekarl, M.

26/02/2025 → 05/03/2025

2 elementer af Mediedækning

Personlig medicin virker - men ofte kan danske kræftpatienter ikke få adgang til behandlingerne

Ladekarl, M.

13/03/2025

1 element af Mediedækning

Potentielt praksisændrende: Nyt antistof øger overlevelsen mod kræft i mavesæk og mavemund

Ladekarl, M.

23/01/2023 → 24/01/2023

2 elementer af Mediedækning

SPØRG OS

Ladekarl, M.

17/02/2022

1 element af Mediedækning

Succes med RAS-hæmmer giver håb om en ny kategori af kræftbehandlinger

Ladekarl, M.

10/01/2021

1 element af Mediedækning

Sundhedsstyrelsen har sammensat nyt rådgivende panel

Ladekarl, M. & El-Galaly, T. C.

02/11/2023

1 element af Mediedækning

Vigtig viden går tabt: Onkologer ønsker systematisk indsamling af data om ikke-anbefalede lægemidler

Ladekarl, M.

12/03/2025 → 14/03/2025

4 elementer af Mediedækning

Aalborg Universitetshospital indfører personaliseret kræftbehandling

Ladekarl, M.

18/11/2020

1 element af Mediedækning

Projekter

EPIC-1: A phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer

Flak, R. V. (Projektkoordinator), Ladekarl, M. (PI (principal investigator)), Poulsen, L. Ø. (Projektkoordinator), Thorlacius-Ussing, O. (Andet), Stender, M. T. (Andet), Detlefsen, S. (Col (co-investigator)), Agger, R. (Col (co-investigator)), Kofod-Olsen, E. (Col (co-investigator)) & Wanders, A. (Col (co-investigator))

01/01/2021 → 09/04/2024

Research profile

Clinical trials; targeted therapy; genomics; diagnostics; cancer immunology, pathology and epidemiology; gastrointestinal and rare cancers.

Leadership

Professor in oncology and precision medicine, Aalborg (2019-). Former head of GI cancer section and Unit for Experimental Cancer Treatment, Aarhus University Hospital. Member of NBH expert committee for experimental cancer treatment (2015-). Member of Danish Medical Medicines Councils advisory board (2014-). Board member of national multidisciplinary groups for pancreatic, hepato-biliary and gastro-esophageal tumors. Member of the Danish Comprehensive Cancer Center steering committee (2021-), and the ctDNA Center steering committee (2020-). Member of National Genome Center advisory boards (2021-). Chair of one international and three regional scientific meetings.

Current clinical trials

PI of Proseq study of personalized medicine

EPIC-1 trial (NCT04835402) of immunotherapy in pancreatic cancer

Pantax Ib trial (NCT04652206) targeting therapy resistance in pancreatic cancer

DPCG-01 randomized trial of chemotherapy in fragile patients with pancreatic cancer.

Supervisor and Examiner Responsibilities

Prior supervisor for 2 PhD-students at Health, University of Aarhus.

Current supervisor for 3 PhD-students at Health, University of Aalborg.

Member/head of the evaluation committee for 7 PhD and 2 doctoral dissertations.

Application reviews

Protocol reviews for EORTC, the Dutch Research Council (NWO) and EU.

Research grants

Active grants from Danish Cancer Society, Danish Regions, Brogaards Foundation, Scandion Oncology A/S, and the NBH.

Scientific Journal Involvement

Member of reviewer board for Journal of Cancers.

Advisory board member of Framingham on HCC (2008-12).

Guest editor for Scientific World Journal (2012) and Journal of Clinical Medicine (2021).

More than 37 peer reviews for at least 14 different international journals.